Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray c...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neoplasia
Главные авторы: Jacobsen, Frank, Kraft, Juliane, Schroeder, Cornelia, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar S., Simon, Ronald, Sauter, Guido, Izbicki, Jakob R., Clauditz, Till S., Luebke, Andreas M., Hinsch, Andrea, Wilczak, Waldemar, Wittmer, Corinna, Büscheck, Franziska, Höflmayer, Doris, Minner, Sarah, Tsourlakis, Maria Christina, Huland, Hartwig, Graefen, Markus, Budäus, Lars, Thederan, Imke, Salomon, Georg, Schlomm, Thorsten, Melling, Nathaniel
Формат: Artigo
Язык:Inglês
Опубликовано: Neoplasia Press 2017
Предметы:
Original article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5565634/
https://ncbi.nlm.nih.gov/pubmed/28830008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.06.003
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы